Xenograft tumor models:
Immunodeficiency mouse models such as nude (nu) strains and the severe combined immunodeficiency (scid) strains most commonly used for human xenograft tumor transplantation. Nudes (nu) functionally deficient of T-cell and other defects therefore, easy to measure the subcutaneous tumor growth . The SCID mice also deficient of functional T-cells and B-cells and readily accept human xenograft. Both of these disease models mimics human diseases and provides very useful information.
Invitek offers in vivo xenograft tumor models in both nude (nu) and the severe immunodeficiency (scid) strains. Tumors transplanted using human carcinoma cell lines used for evaluating therapeutic properties of new drugs and formulations.
- Breast Cancer: MCF-7; MDA-MB231 and ZR-75-1
- Prostate Cancer: DU-145, PC-3 and LANcaP
- Colorectal Cancer: COLO 205, HT-29 and HCT-116,
- Liver Cancer: HepG-2 and Huh7
- Renal Cancer: A-498
- Pancreatic Cancer: Mia PaCa2, AsPc-1,PANC-1, HPAF-II, and BxPc-3
- Glioblastoma: U-87 MG and U118
- Gastric Cancer: AGS and NCI-N87 (N87)
- Lung Cancer: H-460, H-358, and A-549
- Leukemia (Peripheral Blood): HL-60 and K-562
- Melonoma skin cancer: A-375
- Teratocarcinoma: NT2
“Invitek intends to establish more cell lines of the NCI panel which are tumorigenic in mice.”
Syngenic tumor models:
Invitek also offers syngenic tumor models. Tumors developed by using tissue from the same genetic background strain of mouse and used for testing and evaluating new drugs and formulations.
Measurement of Tumor Volume
Tumor volume (mm3) measured with calipers and calculated as (W2 x L) / 2, where W is width and L is length.
The tumor volume at day n is expressed as Relative Tumor Volume (RTV) and caculated according to the following formula: RTV = TVn/TV0, where TVn is the tumor volume at day n and TV0 is the tumor volume at day 0.
The T/C% is determined by calculating RTV as T/C% = 100 x (mean RTV of treated group)/(mean RTV of control group).
The tumor growth inhibition rate (IR) calculated using the formula IR (%) = (1 – TWt/TWc) x 100, where TWt and TWc are the mean tumor weight of treated and control groups, respectively.